



ISOGENICA ANNOUNCES APPOINTMENT OF DR BJÖRN COCHLOVIUS AS CHAIRMAN OF THE BOARD OF DIRECTORS

December 9, 2019
Cambridge, UK

Isogenica Ltd., a leader in the use of synthetic biology and *in vitro* display for the discovery and optimisation of novel single domain biotherapeutics, announced today that Jan-Olof Lundin, Non-Executive Chairman of the Board of Directors (the “Board”) will retire from the Board effective 31 December 2019. He will be succeeded by Dr Björn Cochlovius, currently a Non-Executive Director of Isogenica Ltd., who has been named Chairman of the Board, effective 1 January 2020.

“I am very proud of what Isogenica has accomplished in the last decade” said Jan-Olof Lundin. “Isogenica has become an established presence in antibody discovery building on its synthetic libraries and CIS Display technology, which our team has combined to provide a powerful discovery engine for next generation antibodies.”

“Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical asset and eleven partnered pre-clinical and discovery stage programmes. I believe it is the right time for me to hand over the reins to a new leader. Björn brings exceptional technical and commercial knowledge to the Board, and I am confident that he and Chief Executive Officer Dr Emma Seats and our skilled staff will make a formidable team, driving Isogenica to a successful future.”

“A deep pipeline of therapeutic projects, robust technologies and a great team provide a strong foundation for Isogenica’s future growth” said Dr Cochlovius. “I look forward to working with the Board, Emma and the team to build value for our shareholders, partners and employees.”

In his role as Chairman, Dr Cochlovius will work closely with the CEO and leadership team to prioritize and deliver ongoing expansion and business development activities, form new strategic relationships and build investor relations.

Prior to joining Isogenica in 2019 Dr Cochlovius served as Senior Director of Development (Strategy) at Abbvie and brings 20 years of biopharmaceutical discovery, clinical development and commercial experience to the Board. Dr Cochlovius previously held positions in research and development, business development and mergers and acquisitions at companies including Affitech AS, Roche and Otsuka. Dr Cochlovius started his career developing diabodies and tandem diabodies: fully human recombinant bispecific antibodies. He became the youngest department head at the German Cancer Research Centre (dkfz), after a PhD in immunology and oncology obtained at the Universität des Saarlandes.



About Isogenica

Isogenica is an antibody discovery biotechnology company specializing in single-domain antibody therapeutics. These small format antibodies can be readily incorporated into gene and cell therapies, antibody-drug conjugates and bi- and multi-specific antibody therapeutics making them a highly versatile platform for drug development. The company's fully synthetic single domain library, LlamdA™, is designed from the DNA up, to eliminate liabilities and improve the biophysical traits of library antibodies. Combined with CIS Display, Isogenica's proprietary antibody display platform which enables the full diversity of the company's massive libraries to be displayed, the company has a unique and proven engine for therapeutic antibody discovery and development. Working in collaboration with biopharmaceutical partners over the last decade the company has developed a deep pipeline including one clinical stage asset and eleven partnered pre-clinical and discovery stage programmes.

For more information, visit: www.isogenica.com

Contact:

Mandeep Sehmi, Business Development

T: +44 1799 533 680

E: mandeep.sehmi@isogenica.com